The growth in India pharma exports FY26 has been supported by sustained demand across key global markets. The United States continues to remain the largest export destination, accounting for nearly 34% of total shipments, followed by Europe with a significant share.
Key Highlights
India currently exports pharmaceutical products to over 200 countries, reinforcing its position as a global healthcare supplier and earning the reputation of being the “pharmacy of the world.”
Despite pricing pressures, supply chain disruptions, and global trade volatility, the pharmaceutical sector has maintained a steady growth trajectory. Industry leaders have highlighted that India pharma exports continue to expand due to competitive pricing, strong regulatory compliance, and high-quality manufacturing standards.
The sector had earlier recorded exports of $30.47 billion in FY25, reflecting strong year-on-year growth and setting a solid base for continued expansion.
Growth Drivers: Formulations, Vaccines and Biologicals
Key segments driving export growth include:
Also Read: US Tariffs on Patented Pharma Imports Hit Global Supply
India remains one of the largest suppliers of generic medicines globally, contributing significantly to healthcare systems in developed and emerging markets alike.
The outlook for India pharma exports remains highly positive, with industry estimates projecting the sector to grow to nearly $130 billion by 2030. Growth is expected to be driven by increasing global demand for affordable medicines, expansion into regulated markets, government initiatives and production-linked incentives (PLI), and rising investments in research and development.
